Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM. https://www.cadwalader.com/news/news-release/cadwalader-advises-healthcare-royalty-partners-in-150-million-royalty-agreement-with-karyopharm-therapeutics-ira-schacter